Voyager program scientist at NASA Headquarters in Washington, in a statement. “Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics ...
The same capsid in the VY1706 (tau silencing) gene therapy program achieved desired activity levels and was well-tolerated in three-month NHP studies. Voyager no longer anticipates filing an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results